ScreenerHero

IMTX Immatics N.V.

NAS · US · Healthcare · Biotechnology · immatics.com
7.450USD-0.67%Mkt Cap: 1.13B $P/E: —

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.13B USD
Enterprise Value646.43M USD
Revenue (TTM)41.70M USD
Gross Profit-176.71M USD
Net Income (TTM)-196.45M USD
Revenue/Share0.32 USD
Last Price7.450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees704
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.63
PEG—
EV/EBITDA-2.96
EV/Revenue15.50
P/S27.38
P/B2.28
EPS (TTM)-1.87
EPS (Forward)-2.07
52W Range
7.3103% of range12.41
52W High12.41 USD
52W Low7.310 USD
Profitability
Gross Margin0.00%
Oper. Margin-734.95%
EBITDA Margin0.00%
Profit Margin-407.01%
ROE-40.58%
ROA-34.93%
Growth
Revenue Growth93.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-176.63M USD
CapEx (TTM)6.80M USD
FCF Margin-303.43%
FCF Yield-11.16%
Net Debt-378.74M USD
Net Debt/EBITDA1.74
Balance Sheet
Debt/Equity0.03
Current Ratio7.54
Quick Ratio7.02
Book Value/Sh3.29 USD
Cash/Share2.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)17.63 USD
Upside (mean)+136.7%
Target Range11.80 USD – 25.00 USD
11.80+136.7% to mean25.00
# Analysts6
Ownership
Shares Out.152.23M
Float70.12M
Insiders15.78%
Institutions66.82%
Short Interest
Short Ratio6.7d
Short % Float4.04%
Short % Out.2.92%
Shares Short4.44M
Short (prev mo.)4.92M
Technical
SMA 509.005 (-17.3%)
SMA 2009.840 (-24.3%)
Beta1.36
S&P 52W Chg16.45%
Avg Vol (30d)748.64K
Avg Vol (10d)1.01M
Technical Indicators
RSI (14)30.5
MACD-0.3917
MACD Signal-0.2809
MACD Hist.-0.1108
BB Upper9.522 USD
BB Middle8.469 USD
BB Lower7.415 USD
BB Width24.88%
ATR (14)0.4430 USD
Vol Ratio (20d)1.17x